Expressive

rs11693221 - MEIS1

Magnitude 2.2 · 2 studies on file

Reported associations

  • Genetics of sleep medication purchases suggests causality from sleep problems to psychiatric traits - Unknown journal (n.d.) · Unknown authors · PubMed 37982563

    ABSTRACT: Abstract Study Objectives Over 10% of the population in Europe and in the United States use sleep medication to manage sleep problems. Our objective was to elucidate genetic risk factors and clinical correlates that contribute to sleep medication purchase and estimate the comorbid impact of sleep problems. Methods We performed epidemiological analysis for psychiatric diagnoses, and genetic association studies of sleep medication purchase in 797 714 individuals from FinnGen Release 7 (N = 311 892) and from the UK Biobank (N = 485 822). Post-association analyses included genetic correlation, co-localization, Mendelian randomization (MR), and polygenic risk estimation. Results In a GWAS we identified 27 genetic loci significantly associated with sleep medication, located in

  • Genome-wide association studies and cross-population meta-analyses investigating short and long sleep duration - Unknown journal (n.d.) · Unknown authors · PubMed 37770476

    ABSTRACT: Sleep duration has been linked to a wide range of negative health outcomes and to reduced life expectancy. We present genome-wide association studies of short ( ≤ 5 h) and long ( ≥ 10 h) sleep duration in adults of European (N = 445,966), African (N = 27,785), East Asian (N = 3141), and admixed-American (N = 16,250) ancestry from UK Biobank and the Million Veteran Programme. In a cross-population meta-analysis, we identify 84 independent loci for short sleep and 1 for long sleep. We estimate SNP-based heritability for both sleep traits in each ancestry based on population derived linkage disequilibrium (LD) scores using cov-LDSC. We identify positive genetic correlation between short and long sleep traits (rg = 0.16 ± 0.04; p = 0.0002), as

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • Sleep optimization and management strategies Moderate

    Research indicates patients with sleep problems benefit significantly from sleep care, including sleep hygiene, cognitive behavioral therapy, and when necessary, sleep medications (non-benzodiazepines).

    Discuss sleep difficulties with physician; explore behavioral approaches first, then consider pharmacological options if needed.

Lifestyle

  • Sleep duration and quality High

    rs11693221 in MEIS1 is a genome-wide significant genetic variant associated with short sleep duration (≤5 hours), identified in 430,004 individuals with p=7.0e-9 and replicated in UK Biobank.

    Track average nightly sleep hours; note sleep quality and daytime functioning.

Screening

  • Depression and anxiety symptoms High

    Mendelian randomization analysis shows short sleep duration causally increases major depressive disorder risk (β=0.19, p=1.5e-19) and anxiety risk. Genetic predisposition to short sleep increases psychiatric risk.

    Regular screening for depressive mood and anxiety symptoms; discuss any concerns with healthcare provider.

  • Metabolic health markers Moderate

    Short sleep duration shows significant genetic correlation with obesity (rg=0.23), type 2 diabetes (rg=0.20), and coronary artery disease (rg=0.23). Genetic predisposition to short sleep may increase metabolic disease risk.

    Periodic screening for weight, fasting glucose, lipid panel; cardiovascular risk assessment.